Thermo Fisher Scientific (TMO) Scheduled to Post Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) is scheduled to post its quarterly earnings results before the market opens on Wednesday, April 24th. Analysts expect Thermo Fisher Scientific to post earnings of $4.71 per share for the quarter. Thermo Fisher Scientific has set its FY 2024 guidance at 20.950-22.000 EPS and its FY24 guidance at $20.95 to $22.00 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business’s revenue was down 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.40 EPS. On average, analysts expect Thermo Fisher Scientific to post $22 EPS for the current fiscal year and $24 EPS for the next fiscal year.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $548.37 on Tuesday. The firm has a market cap of $209.32 billion, a price-to-earnings ratio of 35.49, a PEG ratio of 2.30 and a beta of 0.80. The stock has a 50 day moving average of $571.30 and a 200-day moving average of $528.18. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. HSBC raised their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,277 shares of company stock valued at $28,513,384. Corporate insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.